A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study

NCT00432679 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

149

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Rosiglitazone (BRL49653C)

Sponsor

GlaxoSmithKline